Ketamine Therapy for Treatment-Resistant Depression (TRD)
Research studies have shown that untreated depression adversely affects the brain and can cause long-term damage as well as increase the risk for cognitive impairment. Esketamine, a drug made from ketamine, has been approved by the FDA and proven to be effective for patients who do not respond to traditional antidepressant treatment. Dr. Adam Kaplin, founder and initial clinical director of the Johns Hopkins Psychiatric Esketamine Clinic, will discuss esketamine therapy and its potential to provide relief from treatment resistant major depression with or without acute suicidal ideation or behavior. Discussion will include: history and development, current research, mechanisms of action, risks and benefits of eskatimine therapy, how to assess patients for potential esketamine therapy, and future directions for es/ketamine treatment.
Featuring: Adam Kaplin, MD. Dr. Kaplin is a neuropsychiatrist in Baltimore, MD specializing in the treatment of individuals with central nervous system (CNS) neuroinflammatory diseases, such as multiple sclerosis (MS) and related MS spectrum disorders. Dr. Kaplin also treats individuals with other neuroinflammatory diseases with neuropsychiatric symptoms. He is the former principal psychiatric consultant to Johns Hopkins Multiple Sclerosis Center of Excellence and the founder and initial clinical director of the Johns Hopkins Psychiatric Esketamine Clinic.
Special note: This seminar is scheduled to be held in person. We will be following the State of Maryland's COVID-19 guidelines, as well as other safety measures, in place at the time of the seminar. Should the course of COVID-19 change, prohibiting in-person meetings, we may be required to reschedule or offer the seminar remotely.